L3VLUP
ProSign in

HALO · GILD in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

HALOGILD
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • HALO
  • GILD
010203040202120222023202420252026
Holders and value by quarter
QuarterHALOGILD
Q3 20208 holders, $540m25 holders, $14.2bn
Q4 20209 holders, $752m27 holders, $13.4bn
Q1 20217 holders, $712m24 holders, $14.5bn
Q2 20217 holders, $769m18 holders, $14.9bn
Q3 20217 holders, $648m20 holders, $16.4bn
Q4 20218 holders, $635m20 holders, $16.8bn
Q1 20227 holders, $611m28 holders, $13.2bn
Q2 202210 holders, $634m26 holders, $13.6bn
Q3 20228 holders, $537m24 holders, $13.3bn
Q4 20229 holders, $886m32 holders, $21.1bn
Q1 20236 holders, $339m27 holders, $21.8bn
Q2 20236 holders, $394m24 holders, $20.7bn
Q3 20233 holders, $527m24 holders, $20.0bn
Q4 20236 holders, $407m22 holders, $21.5bn
Q1 20245 holders, $326m30 holders, $20.3bn
Q2 20245 holders, $384m28 holders, $18.5bn
Q3 20245 holders, $409m29 holders, $24.2bn
Q4 20248 holders, $335m28 holders, $25.9bn
Q1 20259 holders, $539m33 holders, $32.0bn
Q2 202510 holders, $422m27 holders, $30.9bn
Q3 202514 holders, $1.1bn23 holders, $29.4bn
Q4 202513 holders, $885m25 holders, $34.3bn
Q1 202611 holders, $710m25 holders, $38.5bn
Q2 202611 holders, $732m26 holders, $34.2bn
HALO

Halozyme Therapeutics Inc

Holders
13
Reported value
$885m
Buyers
13
Sellers
23

Breadth -10 among 92 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
GILD

Gilead Sciences Inc

Holders
25
Reported value
$34.3bn
Buyers
18
Sellers
19

Breadth -1 among 92 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q4 2025

Among the 30 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only HALO (5)

D. E. Shaw & Co., Freestone Grove Partners LP, Millennium Management LLC, Two Sigma Investments LP, Voloridge Investment Management LLC

Only GILD (17)

Acadian Asset Management LLC, AQR Capital Management LLC, Brevan Howard Capital Management LP, Capital Research Global Investors, Caxton Associates LLP, Citadel Advisors LLC, Dodge & Cox, Fidelity (FMR LLC), Holocene Advisors LP, Invesco Ltd, Man Group PLC, MFS Investment Management, Neuberger Berman Group LLC, T. Rowe Price Associates Inc, Wellington Management Group LLP, Winton Group Ltd, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →